Publications
68 results found
Athanasopoulou F, Manolakakis M, Vernia S, et al., 2023, Nanodrug delivery systems for metabolic chronic liver diseases: advances and perspectives, NANOMEDICINE, Vol: 18, ISSN: 1743-5889
Xu R, Weber M-C, Hu X, et al., 2022, Annexin A1 based inflammation resolving mediators and nanomedicines for inflammatory bowel disease therapy, SEMINARS IN IMMUNOLOGY, Vol: 61-64, ISSN: 1044-5323
- Author Web Link
- Cite
- Citations: 2
Tillman L, Tabish TA, Kamaly N, et al., 2022, Advancements in nanomedicines for the detection and treatment of diabetic kidney disease., Biomater Biosyst, Vol: 6
In the diabetic kidneys, morbidities such as accelerated ageing, hypertension and hyperglycaemia create a pro-inflammatory microenvironment characterised by extensive fibrogenesis. Radiological techniques are not yet optimised generating inconsistent and non-reproducible data. The gold standard procedure to assess renal fibrosis is kidney biopsy, followed by histopathological assessment. However, this method is risky, invasive, subjective and examines less than 0.01% of kidney tissue resulting in diagnostic errors. As such, less than 10% of patients undergo kidney biopsy, limiting the accuracy of the current diabetic kidney disease (DKD) staging method. Standard treatments suppress the renin-angiotensin system to control hypertension and use of pharmaceuticals aimed at controlling diabetes have shown promise but can cause hypoglycaemia, diuresis and malnutrition as a result of low caloric intake. New approaches to both diagnosis and treatment are required. Nanoparticles (NPs) are an attractive candidate for managing DKD due to their ability to act as theranostic tools that can carry drugs and enhance image contrast. NP-based point-of-care systems can provide physiological information previously considered unattainable and provide control over the rate and location of drug release. Here we discuss the use of nanotechnology in renal disease, its application to both the treatment and diagnosis of DKD. Finally, we propose a new method of NP-based DKD classification that overcomes the current systems limitations.
Kamaly N, Farokhzad OC, Corbo C, 2022, Nanoparticle protein corona evolution: from biological impact to biomarker discovery, NANOSCALE, Vol: 14, Pages: 1606-1620, ISSN: 2040-3364
- Author Web Link
- Cite
- Citations: 12
Basak S, Khare HA, Kempen PJ, et al., 2022, Nanoconfined anti-oxidizing RAFT nitroxide radical polymer for reduction of low-density lipoprotein oxidation and foam cell formation, NANOSCALE ADVANCES, Vol: 4, Pages: 742-753, ISSN: 2516-0230
- Author Web Link
- Cite
- Citations: 3
Morgulchik N, Athanasopoulou F, Chu E, et al., 2021, Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm, INTERFACE FOCUS, Vol: 12, ISSN: 2042-8898
- Author Web Link
- Cite
- Citations: 14
Reischl S, Lee JH, Miltschitzky JRE, et al., 2021, Ac2-26-Nanoparticles Induce Resolution of Intestinal Inflammation and Anastomotic Healing via Inhibition of NF-kappa B Signaling in a Model of Perioperative Colitis, INFLAMMATORY BOWEL DISEASES, Vol: 27, Pages: 1379-1393, ISSN: 1078-0998
Morgulchik N, Kamaly N, 2021, Meta-analysis of In Vitro Drug-Release Parameters Reveals Predictable and Robust Kinetics for Redox-Responsive Drug-Conjugated Therapeutic Nanogels, ACS APPLIED NANO MATERIALS, Vol: 4, Pages: 4256-4268
- Author Web Link
- Cite
- Citations: 11
Bazban-Shotorbani S, Khare HA, Kajtez J, et al., 2021, Effect of Nanoparticle Biophysicochemical Properties on Binding and Transport across Cardiovascular Endothelial Dysfunction Models, ACS APPLIED NANO MATERIALS, Vol: 4, Pages: 4077-4091
- Author Web Link
- Cite
- Citations: 4
Bazban-Shotorbani S, Gavins F, Kant K, et al., 2021, A Biomicrofluidic Screening Platform for Dysfunctional Endothelium-Targeted Nanoparticles and Therapeutics, ADVANCED NANOBIOMED RESEARCH, Vol: 2, ISSN: 2699-9307
Basak S, Khare HA, Roursgaard M, et al., 2021, Simultaneous Cross-Linking and Cross-Polymerization of Enzyme Responsive Polyethylene Glycol Nanogels in Confined Aqueous Droplets for Reduction of Low-Density Lipoprotein Oxidation, BIOMACROMOLECULES, Vol: 22, Pages: 386-398, ISSN: 1525-7797
- Author Web Link
- Cite
- Citations: 6
Jahanshahi M, Kowsari E, Haddadi-Asl V, et al., 2020, An innovative and eco-friendly modality for synthesis of highly fluorinated graphene by an acidic ionic liquid: Making of an efficacious vehicle for anti-cancer drug delivery, APPLIED SURFACE SCIENCE, Vol: 515, ISSN: 0169-4332
- Author Web Link
- Cite
- Citations: 28
Jahanshahi M, Kowsari E, Haddadi-Asl V, et al., 2019, Sericin grafted multifunctional curcumin loaded fluorinated graphene oxide nanomedicines with charge switching properties for effective cancer cell targeting, INTERNATIONAL JOURNAL OF PHARMACEUTICS, Vol: 572, ISSN: 0378-5173
- Author Web Link
- Cite
- Citations: 24
Chung BL, Kaplinsky J, Langer R, et al., 2019, Delivery of Cancer Nanotherapeutics, NANOTHERANOSTICS FOR CANCER APPLICATIONS, Editors: Rai, Morris, Publisher: SPRINGER INTERNATIONAL PUBLISHING AG, Pages: 163-205, ISBN: 978-3-030-01773-6
- Author Web Link
- Cite
- Citations: 1
Bahmani B, Vohra I, Kamaly N, et al., 2018, Active targeted delivery of immune therapeutics to lymph nodes, CURRENT OPINION IN ORGAN TRANSPLANTATION, Vol: 23, Pages: 8-14, ISSN: 1087-2418
Choi WI, Sahu A, Vilos C, et al., 2017, Bioinspired Heparin Nanosponge Prepared by Photo-crosslinking for Controlled Release of Growth Factors, SCIENTIFIC REPORTS, Vol: 7, ISSN: 2045-2322
- Author Web Link
- Cite
- Citations: 19
Yu M, Amengual J, Menon A, et al., 2017, Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr(-/-) Mice, ADVANCED HEALTHCARE MATERIALS, Vol: 6, ISSN: 2192-2640
Foster C, Watson A, Kaplinsky J, et al., 2017, Improved Targeting of Cancers with Nanotherapeutics., Methods Mol Biol, Vol: 1530, Pages: 13-37
Targeted cancer nanotherapeutics offers numerous opportunities for the selective uptake of toxic chemotherapies within tumors and cancer cells. The unique properties of nanoparticles, such as their small size, large surface-to-volume ratios, and the ability to achieve multivalency of targeting ligands on their surface, provide superior advantages for nanoparticle-based drug delivery to a variety of cancers. This review highlights various key concepts in the design of targeted nanotherapeutics for cancer therapy, and discusses physicochemical parameters affecting nanoparticle targeting, along with recent developments for cancer-targeted nanomedicines.
Kamaly N, He JC, Ausiello DA, et al., 2016, Nanomedicines for renal disease: current status and future applications, NATURE REVIEWS NEPHROLOGY, Vol: 12, Pages: 738-753, ISSN: 1759-5061
Cisterna BA, Kamaly N, Choi WI, et al., 2016, Targeted nanoparticles for colorectal cancer, NANOMEDICINE, Vol: 11, Pages: 2443-2456, ISSN: 1743-5889
Kamaly N, Fredman G, Fojas JJR, et al., 2016, Targeted Interleukin-10 Nanotherapeutics Developed with.a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis, ACS NANO, Vol: 10, Pages: 5280-5292, ISSN: 1936-0851
Kamaly N, Yameen B, Wu J, et al., 2016, Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release, CHEMICAL REVIEWS, Vol: 116, Pages: 2602-2663, ISSN: 0009-2665
- Author Web Link
- Cite
- Citations: 1700
Habibi N, Kamaly N, Memic A, et al., 2016, Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery, NANO TODAY, Vol: 11, Pages: 41-60, ISSN: 1748-0132
- Author Web Link
- Cite
- Citations: 399
Chiasson R, Hasan M, Al Nazer Q, et al., 2016, The Use of Silk in Nanomedicine Applications, NANOMEDICINE, Editors: Howard, VorupJensen, Peer, Publisher: SPRINGER, Pages: 245-278, ISBN: 978-1-4939-3632-8
- Author Web Link
- Cite
- Citations: 5
Chung BL, Toth MJ, Kamaly N, et al., 2015, Nanomedicines for endothelial disorders, NANO TODAY, Vol: 10, Pages: 759-776, ISSN: 1748-0132
- Author Web Link
- Cite
- Citations: 40
Miller MA, Gadde S, Pfirschke C, et al., 2015, Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle, Science Translational Medicine, Vol: 7, ISSN: 1946-6234
Therapeutic nanoparticles (TNPs) have shown heterogeneous responses in human clinical trials, raising questions of whether imaging should be used to identify patients with a higher likelihood of NP accumulation and thus therapeutic response. Despite extensive debate about the enhanced permeability and retention (EPR) effect in tumors, it is increasingly clear that EPR is extremely variable; yet, little experimental data exist to predict the clinical utility of EPR and its influence on TNP efficacy. We hypothesized that a 30-nm magnetic NP (MNP) in clinical use could predict colocalization of TNPs by magnetic resonance imaging (MRI). To this end, we performed single-cell resolution imaging of fluorescently labeled MNPs and TNPs and studied their intratumoral distribution in mice. MNPs circulated in the tumor microvasculature and demonstrated sustained uptake into cells of the tumor microenvironment within minutes. MNPs could predictably demonstrate areas of colocalization for a model TNP, poly(D,L-lactic-co-glycolic acid)-b-polyethylene glycol (PLGA-PEG), within the tumor microenvironment with >85% accuracy and circulating within the microvasculature with >95% accuracy, despite their markedly different sizes and compositions. Computational analysis of NP transport enabled predictive modeling of TNP distribution based on imaging data and identified key parameters governing intratumoral NP accumulation and macrophage uptake. Finally, MRI accurately predicted initial treatment response and drug accumulation in a preclinical efficacy study using a paclitaxel-encapsulated NP in tumor-bearing mice. These approaches yield valuable insight into the in vivo kinetics of NP distribution and suggest that clinically relevant imaging modalities and agents can be used to select patients with high EPR for treatment with TNPs.
Fredman G, Kamaly N, Spolitu S, et al., 2015, Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice (vol 7, 277er20, 2015), SCIENCE TRANSLATIONAL MEDICINE, Vol: 7, ISSN: 1946-6234
- Author Web Link
- Cite
- Citations: 8
Leoni G, Neumann P-A, Kamaly N, et al., 2015, Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair, JOURNAL OF CLINICAL INVESTIGATION, Vol: 125, Pages: 1215-1227, ISSN: 0021-9738
- Author Web Link
- Cite
- Citations: 228
Fredman G, Kamaly N, Spolitu S, et al., 2015, Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice, Science Translational Medicine, Vol: 7, ISSN: 1946-6234
Chronic, nonresolving inflammation is a critical factor in the clinical progression of advanced atherosclerotic lesions. In the normal inflammatory response, resolution is mediated by several agonists, among which is the glucocorticoid-regulated protein called annexin A1. The proresolving actions of annexin A1, which are mediated through its receptor N-formyl peptide receptor 2 (FPR2/ALX), can be mimicked by an amino-terminal peptide encompassing amino acids 2–26 (Ac2-26). Collagen IV (Col IV)–targeted nanoparticles (NPs) containing Ac2-26 were evaluated for their therapeutic effect on chronic, advanced atherosclerosis in fat-fed Ldlr−/− mice. When administered to mice with preexisting lesions, Col IV–Ac2-26 NPs were targeted to lesions and led to a marked improvement in key advanced plaque properties, including an increase in the protective collagen layer overlying lesions (which was associated with a decrease in lesional collagenase activity), suppression of oxidative stress, and a decrease in plaque necrosis. In mice lacking FPR2/ALX in myeloid cells, these improvements were not seen. Thus, administration of a resolution-mediating peptide in a targeted NP activates its receptor on myeloid cells to stabilize advanced atherosclerotic lesions. These findings support the concept that defective inflammation resolution plays a role in advanced atherosclerosis, and suggest a new form of therapy.
Choi WI, Kamaly N, Riol-Blanco L, et al., 2014, A Solvent-Free Thermosponge Nanoparticle Platform for Efficient Delivery of Labile Proteins, NANO LETTERS, Vol: 14, Pages: 6449-6455, ISSN: 1530-6984
- Author Web Link
- Cite
- Citations: 33
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.